SEATTLE – February 17, 2026 – Fred Hutch Cancer Center scientists reached a crucial milestone in blocking Epstein-Barr virus (EBV), a pathogen estimated to infect 95% of the global population that is ...

Fred Hutch Cancer Center scientists reached a crucial milestone in blocking Epstein Barr virus (EBV), a pathogen estimated to infect 95% of the global population that is linked to multiple types of ...

Most people have the Epstein-Barr (EBV) virus. Sometimes people are unaware of this virus in their body; it settles into immune cells and remains for the duration. Although EBV does not cause illness ...

Constant exposure to diverse diseases is an occupational hazard for all healthcare workers, especially those who work with children. Scientists have now plumbed the immune systems of pediatricians to ...

Respiratory syncytial virus (RSV) is a common respiratory virus which usually causes mild, cold-like symptoms during the respiratory virus season. However, especially among young infants under six ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – a leading precision medicine company focused on the discovery, development, and commercialization of clinically ...

Researchers have developed a new type of flu treatment that could have a dramatic impact on the fight against influenza and potentially, other viruses too. This method involves an antibody cocktail, ...

Scientists at the Jackson Laboratory (JAX) have developed an antibody-based therapy against influenza A virus (IAV), which they suggest could change the way the world fights flu, one of the deadliest ...

In a prospective study of patients with stages I-III Merkel cell carcinoma (MCC), seropositivity for rising polyomavirus oncoprotein antibody titers conferred a 58% risk for recurrence at 12 months, ...

What makes Zika especially dangerous is its ability to hide in protected areas of the body, including the brain, eyes and reproductive organs, where it can linger undetected. Even more troubling, Zika ...

Casi Pharmaceuticals Inc. announced the U.S. FDA has cleared its IND application for CID-103, a monoclonal antibody targeting CD-38 for the prevention of antibody-mediated rejection (AMR) of kidney ...